Alexza Pharmaceuticals
Alexza Pharmaceuticals - Alexza Pharmaceuticals - Welcome.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | $5.0m | Post IPO Equity | |
| Total Funding | 000k | ||
Related Content
Founded in 2000 by Alejandro Zaffaroni and Thomas B. King, Alexza Pharmaceuticals embarked on a mission to innovate drug delivery systems. The company focused on developing proprietary products for acute and intermittent conditions, utilizing their unique Staccato system. This technology allowed for rapid drug delivery through inhalation, offering a novel approach to treatment.
In March 2006, Alexza Pharmaceuticals made a significant leap by going public. The company staged its Initial Public Offering (IPO), pricing 5.5 million shares at $8 each. This move was pivotal, providing the necessary capital to advance their research and development efforts.
A decade later, in May 2016, Alexza Pharmaceuticals experienced another major milestone. The company was acquired by Grupo Ferrer Internacional for $55 million. This acquisition marked a new chapter, integrating Alexza's innovative technologies with Ferrer's global reach and resources.
Throughout its journey, Alexza Pharmaceuticals remained committed to transforming patient care through its cutting-edge inhalation therapies. The company's story is a testament to the impact of innovation in the pharmaceutical industry, highlighting the potential of novel drug delivery systems to improve treatment outcomes.